<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01666249</url>
  </required_header>
  <id_info>
    <org_study_id>IMUPAN1011</org_study_id>
    <nct_id>NCT01666249</nct_id>
  </id_info>
  <brief_title>Clinical Efficacy of Postpartum Immunization of Rh and Coombs Negative Women With Sensitization Risk.</brief_title>
  <official_title>Evaluation of the Clinic Efficacy of Immunoglobulin Anti-RhD KamRho-D® (Panamerican) in Postpartum Immunization of Rh-negative and Coombs Negative Women at Sensitization Risk.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azidus Brasil</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Panamerican Medical Supply Suprimentos Médicos Ltda.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azidus Brasil</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The anti-Rh immunoglobulin is an immunobiological containing high concentration of specific
      antibodies against factor D and &quot;neutralizes&quot; D antigen present in the Rh-positive fetal red
      blood cells (Rh +), which passed into the bloodstream of Rh-negative pregnant women (Rh).
      This a immunization study for clinical assessment of anti-Rh immunoglobulin (KamRho-D®) in Rh
      and Coombs negative women with risk sensitization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This a immunization, non-randomized phase III study in which women participants with RH and
      Coombs negative receive only one dose of 1500 IU anti-Rh immunoglobulin intramuscularly and
      will be following during six months to verification of negative Coombs maintenance. Safety
      evaluation data will include report of all adverse events (including type, frequency,
      intensity, seriousness, severity and action taken related to the investigational product).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint will be the maintenance of the negative result for the indirect Coombs test 06 months after delivery, proving that the test drug had the same ability to neutralize possible fetal red blood cells.</measure>
    <time_frame>72 (+6) hours after immunization; 90 days after immunization and 180 days after immunization.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence, intensity, type and frequence of adverse event.</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">232</enrollment>
  <condition>Pregnancy; Fetomaternal Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Immunoglobulin Anti-RhD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KamRho-D (Panamerican)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Immunoglobulin Anti-RhD</intervention_name>
    <description>KamRho-D (Immunoglobulin Anti-RhD): single dose (300mcg/2mL), via intramuscular, up to 72h after delivery.</description>
    <arm_group_label>Immunoglobulin Anti-RhD</arm_group_label>
    <other_name>KamRho-D</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Agree to participate, sign and date the Informed Consent;

          -  18 years old or older;

          -  Mothers who are Rh-negative, negative indirect Coombs analyzed by gel agglutination
             method, whose just deliveries Rh positive baby.

        Exclusion Criteria:

          -  Be participating simultaneously or have participated in another clinical trial within
             the last 12 months;

          -  Mothers who are allergic to any components of the formula;

          -  Mothers who have a history of IgA deficiency or IgA antibody present;

          -  Mothers who have a history of autoimmune hemolytic anemia with hemolysis or with
             pre-existing risk of hemolysis;

          -  Mothers who have indirect Coombs test positive in the beginning of the treatment;

          -  Rh-negative mothers whose delivered Rh-negative babies;

          -  Abnormalities of the coagulation system;

          -  Patients who made use of vaccines made with live pathogens in the last 03 months or
             will make during the study;

          -  Patients with clinical diagnosis of prenatal liver and / or severe nephropathy;

          -  Principal Investigator of the study criteria;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre Frederico, Physician</last_name>
    <role>Study Director</role>
    <affiliation>Azidus Brasil</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandre Frederico</last_name>
    <phone>+55 11 38716399</phone>
    <email>alexandre@lalclinica.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centro de Pesquisa da MEAC - Maternidade Escola Assis Chateaubriand</name>
      <address>
        <city>Fortaleza</city>
        <state>Ceara</state>
        <zip>60430-270</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daisy Lucena</last_name>
      <email>daisydelucena@yahoo.com.br</email>
    </contact>
    <investigator>
      <last_name>Francisco Edson de Lucena Feitosa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Tropical de Medicina Reprodutiva e Menopausa -INTRO</name>
      <address>
        <city>Cuiaba</city>
        <state>Mato Grosso</state>
        <zip>78043-306</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacklyne Silva Barbosa</last_name>
      <email>jacklynepesquisa@yahoo.com.br</email>
    </contact>
    <investigator>
      <last_name>Sebastião Freitas de Medeiros, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Associação Educadora São Carlos AESC - Centro de Pesquisa HRPC</name>
      <address>
        <city>Canoas</city>
        <state>Rio Grande do Sul</state>
        <zip>92425-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heveline Roesch</last_name>
      <email>heveline.roesch@hrpc.com.br</email>
    </contact>
    <investigator>
      <last_name>Tiane Nogueira Salum, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>vlfreitas@hcpa.edu.br</email>
    </contact>
    <contact_backup>
      <last_name>Vera Lorentz</last_name>
    </contact_backup>
    <investigator>
      <last_name>Eduardo Pandolfi Passos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital São Lucas (Puc-Rs)</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aline Cássia Santos</last_name>
      <phone>+55 51 3320-3479</phone>
      <email>dq.acassia@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Breno José Acauan Filho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2012</study_first_submitted>
  <study_first_submitted_qc>August 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2012</study_first_posted>
  <last_update_submitted>April 7, 2016</last_update_submitted>
  <last_update_submitted_qc>April 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FMH; anti-Rh; efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Fetomaternal Transfusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

